Table 7.24Remission

StudySequenceOutcomesFollow-upResult –best treatment
MASCOT study255
Level 1++
SSZ then SSZ + MTX vs SSZ continuousPercentage of patients with EULAR good response (18% vs 7%) and percentage in remission (10% vs 5%)18 monthsArm 1 (better)
SSZ then SSZ + MTX vs SSZ then MTXPercentage of patients with EULAR good response (18% vs 5%) and percentage in remission (10% vs 3%)18 monthsSimilar
SSZ then MTX vs SSZ continuousPercentage of patients with EULAR good response (5% vs 7%) and percentage in remission (3% vs 5%)18 monthsSimilar
1 RCT (Ferraccioli et al.)260
Level 1+
DMARD then DMARD + MTX vs DMARD then DMARD + SSZMagnusson criteria (full response): 40% vs 21%3 yearsArm 1 (better)
Number of patients in full remission (ACR): 9% vs 7%3 yearsSimilar
DMARD then DMARD + CsA vs DMARD then DMARD + SSZMagnusson criteria (full response): 40% vs 21%3 yearsArm 1 (better)
Number of patients in full remission (ACR) 9% vs 7%3 yearsSimilar
TICORA study242
Level 1++
Intensive vs routineEULAR good response (OR 5.8, 95% CI 2.4 to 13.9), EULAR remission (OR 9.7, 95% CI 3.9 to 23.9)Over the 2 yearsArm 1 (both p <0.0001)
1 cohort study (Hider et al.)263
Level 2+
Starting on SSZ vs starting on MTXPercentage of patients in remission2 and 5 yearsNS

From: 7, Pharmacological management

Cover of Rheumatoid Arthritis
Rheumatoid Arthritis: National Clinical Guideline for Management and Treatment in Adults.
NICE Clinical Guidelines, No. 79.
National Collaborating Centre for Chronic Conditions (UK).
Copyright © 2009, Royal College of Physicians of London.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.